

1 Antimicrobial agents for the treatment of enteric 2 fever chronic carriage: A systematic review

3 Short title: Antimicrobial agents for the treatment of enteric fever
4 chronic carriage

5 McCann N^{1,2}, Scott P^{1,2}, Parry CM^{3,4,5}, Brown M^{1,6}

6

7 1. Hospital for Tropical Diseases, University College London Hospitals NHS
8 Foundation Trust, London, UK

9 2. UCL Faculty of Population Health Sciences, University College London
10 (UCL), London, UK

11 3. Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK

12 4. Alder Hey Children's NHS Foundation Trust. Liverpool, UK

13 5. Centre for Tropical Medicine and Global Health, University of Oxford, Oxford,
14 UK.

15 6. Clinical Research Dept, London School of Hygiene & Tropical Medicine

16

17

18

19

20 *Correspondence to:*

21 *Dr Naina McCann,*

22 Naina.mccann@nhs.net/zchaf30@ucl.ac.uk

23

24 **NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

25 **Abstract**

26 **Background**

27 Chronic carriage of *S. Typhi* or *S. Paratyphi* is an important source of enteric
28 fever transmission. Existing guidance and treatment options for this condition
29 are limited. This systematic review aims to assess the evidence concerning the
30 efficacy of different antimicrobials in treating enteric fever chronic carriage.

31

32 **Methods**

33 We searched major bibliographic databases using relevant keywords between
34 1946 and September 2021. We included all interventional studies that included
35 patients with confirmed enteric fever chronic carriage and deployed an
36 antimicrobial that remains in clinical practice today. Case reports and case series
37 of under 10 patients were excluded. Two reviewers screened abstracts, selected
38 articles for final inclusion and quality-assessed the included studies for risk of
39 bias. Extracted data was analysed, with pooling of data and eradication rates for
40 each antimicrobial calculated. As only one randomised controlled trial was
41 identified no meta-analysis was performed.

42

43 **Results**

44 Of the 593 papers identified by the initial search, a total of eight studies met the
45 inclusion criteria and were included in the systematic review. Evidence was
46 identified for the use of fluoroquinolones and amoxicillin/ampicillin in the
47 treatment for enteric fever chronic carriage. Fluoroquinolones were superior to
48 amoxicillin/ampicillin with 92% of patients eradicated after one antimicrobial

49 course compared to 68% (p = 0.02). The quality of included studies was poor,
50 and all were carried out before 1990.

51

52 **Conclusion**

53 This review identified fluoroquinolones and amoxicillin as treatment options for
54 enteric fever chronic carriage, with fluoroquinolones the more effective option.
55 However, this evidence pre-dates rises in antimicrobial resistance in enteric
56 fever and therefore the significance of these findings to today's practice is
57 unclear. Further research is needed to investigate whether these antimicrobials
58 remain appropriate treatment options or whether alternative interventions are
59 more effective.

60

61

62 **Author summary**

63 There are more than 14 million cases of enteric fever every year globally. The
64 rise of antimicrobial resistance against *S. Typhi* and *S. Paratyphi*, the pathogens
65 causing enteric fever, has led to limited treatment options against this condition.
66 Mechanisms to prevent infection are therefore becoming increasingly important.
67 Public health measures and, more recently, the development and rollout of the
68 typhoid conjugate vaccine, are going some way towards reducing transmission of
69 this condition but identification and treatment of enteric fever chronic carriers
70 has been neglected.

71

72 *S. Typhi* and *S. Paratyphi* are restricted to human hosts and transmitted via the
73 ingestion of contaminated food or water. Chronic carriers, those who
74 asymptotically excrete the pathogens in their stool following infection, play
75 an important role in maintaining the reservoir of infection within humans.
76 Identification and treatment of these carriers will be vital in further reducing
77 transmission of enteric fever and ultimately eliminating this condition.

78

79 Here we review the evidence for antimicrobials in treating enteric fever chronic
80 carriage. We identify evidence for fluoroquinolones and amoxicillin as treatment
81 strategies but highlight large gaps in the literature on this subject, including a
82 lack of evidence in the antimicrobial-resistant era of enteric fever.

83

84 **Introduction**

85

86 Enteric fever is a systemic febrile illness caused by infection with the Gram-
87 negative bacteria *Salmonella enterica* subspecies serovars Typhi (*S. Typhi*) and
88 Paratyphi A, B or C (*S. Paratyphi*). It causes significant morbidity and mortality
89 globally, with approximately 14 million cases and 135,000 deaths per year, with
90 the highest number of reported cases from South and South-East Asia(1).

91

92 Enteric fever is transmitted via the faecal-oral route via the ingestion of food or
93 water contaminated with infected human faeces. Clinical illness usually occurs 7-
94 14 days after exposure with a non-specific febrile illness. The majority of
95 patients recover from acute enteric fever following an appropriate course of

96 antimicrobials. Around 10% of patients continue to excrete *S. Typhi* or *S.*
97 *Paratyphi* in their stool for a few weeks in the convalescent period following
98 recovery from acute infection with approximately 1-5% of patients continuing to
99 excrete *S. Typhi* or *S. Paratyphi* in their stool for more than one year (2,3). This
100 latter group are known as chronic carriers(4).

101

102 The pathogenesis of chronic carriage is not well understood. The gallbladder and
103 biliary system appear to be the site of primary persistence of *S. Typhi* and *S.*
104 *Paratyphi* in chronic carriers and indeed those with gallstones are more likely to
105 become carriers (4–6).

106

107 *S. Typhi* and *S. Paratyphi* are human-restricted pathogens and therefore chronic
108 carriage plays an important role in maintaining the reservoir of infection in
109 humans. Asymptomatic chronic carriers unknowingly transmit the disease to
110 others by faecal contamination of food and water. The first, and perhaps most
111 famous example of this was Mary Mallon ('typhoid Mary') who worked as a chef
112 in New York in the 1950s and infected at least 54 people as an asymptomatic
113 carrier(3). Since then forensic epidemiology has demonstrated many more such
114 cases, for example Mr N the Folkestone milker who infected over 200 people
115 over a number of years via infected milk (7).

116

117 In addition to the public health risk of chronic carriage there is evidence that
118 chronic carriage is associated with an increased individual risk of malignancy,
119 particularly gallbladder cancer (8–10). A recent meta-analysis reported an

120 overall odds ratio of gallbladder cancer in *S. Typhi* carriers of 4.28 (95% CI:
121 1.84–9.96) (11).

122

123 The identification and treatment of chronic carriers therefore has both a
124 significant public health and arguably individual benefit. There is currently
125 limited evidence or guidance on how these chronic carriers should be treated.
126 Furthermore, recent clinical reviews on the subject give differing advice on
127 whether antimicrobials are an effective treatment option for chronic carriage
128 treatment (12–14).

129

130 WHO enteric fever guidelines from 2003 suggest treatment options for enteric
131 fever chronic carriage of amoxicillin, co-trimoxazole or ciprofloxacin (15). Over
132 the last 30 years there have been significant changes in antimicrobial resistance
133 patterns of *S. Typhi* and *S. Paratyphi*, with decreased susceptibility to
134 fluoroquinolones (Fq) now almost universal in some areas of South Asia and
135 increasing across sub-Saharan Africa (16–18). Multi-drug resistance (MDR),
136 resistance to amoxicillin, co-trimoxazole, chloramphenicol, is also seen in around
137 40% of patients worldwide (16). A current outbreak of extensively-drug-
138 resistant (XDR) enteric fever in Pakistan has highlighted the limited
139 antimicrobial treatment options available for acute enteric fever in this setting.
140 The options for antimicrobial treatment of enteric fever chronic carriers in the
141 era of drug-resistance are unknown.

142

143 The aim of this systematic review is to review the existing evidence of efficacy of
144 antimicrobials in treating enteric fever chronic carriage. By doing so we hope to

145 review existing knowledge and highlight areas for ongoing research and review.

146

147 **Methods**

148 The reporting of this systematic review was guided by the standards of the
149 Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA)
150 statement (19). A search of PROSPERO database performed did not reveal any
151 existing similar protocols. The protocol for this review was not registered but
152 can be found in supplementary material (S3)

153

154 **Search strategy and selection criteria**

155 A systematic search through MEDLINE, EMBASE and Web of Science from 1946
156 was initially performed on the 1st February 2021. The terms searched were
157 (“typhoid” OR “paratyphoid” OR “salmonella typhi” OR “salmonella paratyphi
158 “OR “enteric fever”) AND
159 (“chronic carriage” OR “disease carrier “OR “carrier state” OR “typhoid carrier”
160 OR “paratyphoid carrier” AND
161 (“antibiotic” OR “antibacterial” OR “antibacterial treatment” OR “antibiotic
162 treatment” OR “antibacterial agent” OR “antibiotic agent” OR names of individual
163 antibiotics). The full list of search terms is listed in the supplementary
164 information (S1). No language restrictions were included in the initial search.
165 Reference lists and bibliographies of selected articles were also searched. A
166 search for unpublished literature was not performed.

167

168 A repeat search of the same terms was performed in September 2021 to check
169 for any additional studies that could be included prior to publication. All new
170 articles identified that been published since the prior search date were reviewed
171 by two independent reviewers.

172

173 We included studies that met the following criteria:

174 1) Baseline population of adults with confirmed enteric fever chronic

175 carriage

176 2) Intervention of an antimicrobial course

177 3) Outcomes of stool clearance measured as defined by authors of each

178 included study

179

180 We did not include studies that assessed an antimicrobial that is no longer in
181 clinical use today, for example sulphathiazole. Case reports and case series of
182 under 10 cases were excluded to minimize study bias. If studies included
183 participants with non-typhoidal salmonella (NTS) chronic carriage in addition to
184 patients with enteric fever chronic carriage these studies were individually
185 reviewed to assess whether they included 10 or more patients with enteric fever
186 chronic carriage and, if they met other inclusion criteria, they were included.
187 Studies that combined an antimicrobial treatment intervention with another
188 intervention (e.g. cholecystectomy) were only included if they had an
189 intervention arm that included antimicrobials alone and this was made up of \geq
190 10 patients.

191

192 If journal articles were not available online, we requested print versions through
193 store requests in our academic institution. Articles were excluded if we could not
194 access a full-text version for review. Two independent researchers screened
195 titles and abstracts and reviewed full text articles for inclusion with any
196 disagreements resolved by consensus.

197

198 **Quality of studies**

199 Two independent reviewers evaluated the study quality with any disagreements
200 resolved by consensus. Quality assessment was performed using the National
201 Heart, Lung and Blood Institute quality assessment tools (20). Each study was
202 given an overall rating of good, fair or poor.

203

204 **Data extraction**

205 Data extraction was performed using a standardized data extraction form. Data
206 was collected on publication year, study country, study design, participant
207 characteristics including number of patients with gallstones, number of
208 participants given intervention, intervention type including dose and duration,
209 stool culture result at follow-up and side effects of intervention.

210

211 **Data analysis**

212 For each included study the proportion of those chronic carriers that eradicated
213 the pathogen (eradication proportion) was calculated (i.e., the number of
214 participants culture negative for *S. Typhi* or *S. Paratyphi* after an antimicrobial
215 intervention divided by the total number of participants in the study).

216

217 For those that had a control population we calculated the eradication proportion
218 in this population. Data was synthesized for studies using the same antimicrobial
219 intervention and overall eradication proportions presented. The main outcome
220 measure was eradication proportion after one course of antimicrobials. As some
221 studies re-treated their patients' multiple times, we also calculated eradication
222 proportion per antimicrobial course. Other data synthesised for each
223 antimicrobial intervention included intervention characterises and side effects of
224 antimicrobial use. Results were presented in tabular format comparing
225 antimicrobial intervention. Categorical variables were compared using Fishers
226 exact test. Data was collated in Microsoft Excel and analysed in RStudio version
227 1.4.1103.

228

229

230 **Results**

231

232 **Flow of included studies**

233 The initial search strategy identified 579 papers. The abstracts and titles were
234 reviewed and after applying inclusion and exclusion criteria 26 papers were
235 identified for full-text evaluation. Of these a further 18 were excluded for reasons
236 shown in the PRISMA flow-chart in Figure 1, leaving 8 articles which met our
237 inclusion criteria. Full-text manuscripts could not be accessed in 7 cases; all but
238 one of these were published in non-English language journals (3 German, 1
239 Polish, 1 Russian, 1 Japanese). Of these 3 were published before 1960 and the

240 remaining 4 were published before 1980. A further search using the same terms
241 was performed in September 2021 which identified a further 14 papers, none of
242 which were deemed eligible for inclusion.

243

244 **Figure 1.** Preferred Reporting Items for Systematic Reviews (PRISMA) flow
245 diagram of the study selection process

246

247 **Study characteristics**

248 Study characteristics of all included studies are summarised in Table 1. Only one
249 used a blinded randomised-control trial (RCT) design. The remaining seven
250 studies used an open, pre- post design method with no controls, comparing stool
251 culture (outcome measure) in participants before and after treatment.

252

253 Included studies were carried out between 1966 and 1988, with no studies
254 included from the last 30 years. The majority of studies were carried out in the
255 USA (n= 4) with the remaining papers conducted in Chile (n = 1), Peru (n = 1),
256 Italy (n= 1) and Israel (n = 1).

257

258 **Table 1. Summary of included studies**

Study author and references	Country	Year	Journal published	Planned intervention, drug, dose and duration	Study design	Out
--------------------------------	---------	------	----------------------	---	--------------	-----

Ferreccio et al (21)	Chile	1988	Journal of Infectious Diseases	Ciprofloxacin PO 750mg BD, 28 days	Open pre- and post- trial, no control	3 s 3, tre
Gotuzzo et al(22)	Peru	1988	Journal of Infectious Diseases	Norfloxacin PO 400mg BD, 28 days	Double-blind randomised- controlled trial, followed by open trial	St 1,2
Phillips et al (23)	USA	1971	Journal of American Medical Association	Ampicillin PO 1g QDS, 90 days	Open pre- and post- trial, no control	St mi tre
Simon et al (24)	USA	1966	New England Journal of Medicine	Ampicillin PO 75- 100mg/kg/day for 28 days	Open pre- and post- trial, no control	St fir fo tin 7 r
Nolan et al (25)	USA	1978	Journal of American Medical Association	Amoxicillin PO 2g TDS for 28 days	Open pre- and post- trial, no control	St m
Dinbar et al (26)	Israel	1969	American Journal of Medicine	Ampicillin PO 5.25mg/day for 10- 40 days	Open, multi-arm pre- and post- trial, no control	St mi tre
Kaye et al (27)	USA	1967	Annals of the New York Academy of Science	Ampicillin PO 1.5mg QDS + probenecid 0.5g QDS, 42 days	Open pre- and post- trial, no control	St de m

Scioli et al (28)	Italy	1970	Journal of Infectious Diseases	Ampicillin IV 1g TDS, 15 days	Open pre- and post- trial, no control	St fo on of
-------------------	-------	------	--------------------------------	-------------------------------	---------------------------------------	----------------------

259

260

261 Inclusion criteria for almost all the studies was presence of *S. Typhi* or *S.*

262 *Paratyphi* in the stool or bile for greater than 12 months. One study necessitated

263 prior history of acute enteric fever (29) and one study included two patients who

264 had positive stool cultures with an elevated Vi antibody level, without need for

265 repeated positive cultures of > 1 year (30). One study mentioned that included

266 patients had been previously treated for chronic carriage (28) but others did not

267 specify this. Length of chronic carriage varied between participants within

268 studies, with the longest carrier state being 39 years. Two studies excluded those

269 with serious underlying health conditions and patients with penicillin allergies

270 (29,31). Exclusion criteria were not well defined in the other studies.

271

272 The age range of included participants was broad, including adults from 18-81

273 years. One study included one child aged 7 years old with the results not

274 separated from the 14 adults in the study(32). After discussion between

275 reviewers this study was included. The majority of participants in the studies

276 were female which correlates with prior knowledge that females are more likely

277 to be carriers (33).

278

279 Most of the studies investigated participants for underlying gallstones before
280 enrolment in the study using ultrasound or cholangiography or X-ray. However,
281 in some patients the biliary tract was not well visualised and two studies did not
282 investigate for underlying gallstones prior to enrolment (30,34). These patients
283 were categorised in a third category 'gallstone status unknown'.

284

285 **Study intervention**

286 The intervention drug was a fluoroquinolone (Fq) in two studies: norfloxacin
287 was used in one and ciprofloxacin in the other. Four of the studies used
288 ampicillin alone as the intervention, one study used amoxicillin and one used
289 ampicillin with probenecid. One of the ampicillin studies used intravenous
290 administration but the rest of the studies used oral administration. Dosing varied
291 between the different studies (see Table 1). One study also included separate
292 arms of the study with patients undergoing cholecystectomy and
293 cholecystectomy in combination with ampicillin treatment (26). In this study six
294 of the patients undergoing antimicrobial treatment alone had previously
295 undergone cholecystectomy in the other arm of the study. These were included
296 as they were confirmed to still be chronic carriers 1 year post cholecystectomy
297 and prior to enrolment in the antimicrobial arm.

298

299 **Quality assessment**

300 Overall methodological quality of included studies was poor (see Table 1). There
301 was only one randomised and blinded study, with the majority of studies
302 designed as pre- and post-studies without a control.

303 In the RCT study, the outcomes were inconsistently reported with the summary
304 table showing no cases of eradication in the placebo group but the text reporting
305 that one patient this arm did have negative stool cultures at follow-up (indicating
306 spontaneous cure). Furthermore, 13 patients were enrolled in the norfloxacin
307 arm but only 12 patients included in the final analysis with no intention-to-treat
308 analysis performed. No relative risk or odds ratio was calculated.

309

310 The remainder of the studies were open, pre- and post- studies without controls.
311 Overall inclusion criteria were well defined, but studies did not clearly state how
312 patients were enrolled.

313

314 Interventions were generally well defined but often not consistent across
315 participants, with some studies changing dosing regimens during the study
316 period and one study using multiple interventions on participants (26). All
317 studies clearly defined the outcome measure, and this was measured before and
318 after intervention and at repeated intervals for adequate follow-up periods after
319 intervention. Loss to follow-up in the included studies was small (less than 20%
320 in all). None of the studies mentioned a power calculation and numbers of
321 participants were small in all studies. Minimal statistical analysis was performed.

322

323 A meta-analysis was not performed as there was only one RCT identified.

324

325 **Outcomes by antimicrobial group**

326 **Fluoroquinolones**

327 Two studies assessed Fq as a treatment option for *S. Typhi* chronic carriage, and
328 no studies assessed Fq as a treatment option for *S. Paratyphi* chronic carriage. In
329 the *S. Typhi* studies a total of 25 patients received an intervention course
330 (29,35). The norfloxacin study was an RCT, comparing 28-days of 400mg BD
331 norfloxacin to placebo. The ciprofloxacin study was a pre-post study
332 investigating the effect of a 28-day course of 750mg BD ciprofloxacin. All patients
333 had *S. Typhi* chronic carriage, 44% of whom were known to have gallstones
334 (although this was not specifically looked for in one of the studies). Both Fq
335 studies showed an eradication proportion of 92% following a single 28-day
336 treatment course. These two studies are summarised in Table 2.

337

338 **Table 2. Summary of results from studies using fluoroquinolone antibiotics**
339 **to treat *S. Typhi* chronic carriage**

Intervention given	No n	Fluoroquinolone o	Placebo o	Combined interventions o
Participant characteristics				
Total no of participants, n	13	12	12	25
With gallstones, n (%)	9 (69)	9 (75)	2 (17)	11 (44)
Without gallstones, n (%)	4 (31)	3 (25)	0	4 (16)
Unknown gallstone status, n (%)	0 (0)	0	10 (75)	10 (36)
Demographics				
Age, mean	36	35	31	34
Age, range	18-58	12-67	20-51	18-67
Female, n (%)	6 (46)	11 (92)	10 (83)	16 (64)
Microbiological characteristics				
S. Typhi, n (%)	13 (100)	12 (100)	12 (100)	25 (100)
MIC to intervention drug, range (ug/mL)	0.06 – 0.5	0.06-0.5	0.0156-0.0078	0.0078-0.5
Intervention				
Administration method	PO	PO	PO	
Total daily dose, mean (mg)	800	NA	1500	
Total duration, mean (days)	28	28	25	
Duration range, (days)	28	28	10-28	
Outcomes – eradication				
Minimum follow-up (months)	3	3	12	3
Total no of patients included in analysis ¹ , n	12	12	12	24
Total no patients eradicated at end of follow-up, n (%)	11 (92)	1 (8)	11 (92)	22 (92)
Eradicated in those with gallstones, n (%)	7 (88)	1 (8)	2 (100)	9 (82)

<i>Eradicated in those without gallstones, n (%)</i>	4 (100)	0 (0)	0 (0)	4 (100)
<i>Eradicated in those with unknown gallstone status, n (%)</i>	0 (0)	0 (0)	9 (90)	9 (90)
Outcomes – side effects				
<i>Total side effects, n (%)</i>	1 (8)	3 (25)	5 (41)	6 (25)
<i>Diarrhoea, n (%)</i>	0	0	0	0
<i>Rash, n (%)</i>	0	0	1 (8)	1 (4)
<i>Other, n (%)</i>	1 (8)	3 (25)	4 (33)	5 (21)
Total no of antibiotic courses given², n	23	12	12	35
<i>No of antibiotic courses resulting in successful eradication, n (%)</i>	18 (78)	1 (8)	11 (90)	29 (83)

340 1 – One patient was excluded from norfloxacin analysis in Gottuzo paper due poor adherence
 341 2 – In Gotuzzo paper 10 placebo patients were re-treated with norfloxacin openly taking the total
 342 number of treatment courses given in this paper to 23.
 343

344 In the RCT the norfloxacin group had a higher proportion of *S. Typhi* eradication
 345 than the control group (92% vs 8%, $p < 0.001$).
 346

347 **Effect of gallstones on eradication**

348 Patients in the ciprofloxacin study were not routinely screened for biliary
 349 disease before enrolment in the study, however two patients were known to
 350 have gallstones. In the norfloxacin study patients underwent oral
 351 cholecystogram, IV cholangiography or gallbladder ultrasound before enrolment.
 352

353 Eradication proportions were 100% in those without gallstones, 89% in those
 354 with unknown gallstone status and 82% in those with known gallstones.
 355

356 **Side effects**

357 Side effects were seen in a quarter of patients. In the ciprofloxacin study two
 358 patients stopped treatment early due to side effects (haemoglobin drop and

359 urticarial rash). Of note, three other patients in this study had a haemoglobin
360 drop that were attributed to ciprofloxacin therapy. Norfloxacin was relatively
361 well-tolerated in the other study with only one patient reporting a rash, although
362 these are not further explored in this paper.

363

364 ***Effect of repeated courses***

365 In the norfloxacin study patients initially treated with placebo were then
366 retreated with norfloxacin. This group had a slightly lower eradication
367 proportion of 70%, lowering the overall eradication proportion to 83% per
368 antibiotic course overall.

369

370 **Ampicillin/amoxicillin**

371 The remaining six studies identified assessed amoxicillin or ampicillin
372 (amox/amp) use. The results of these are summarized in Table 3.

373

374 **Table 3. Summary of results from studies using amoxicillin or ampicillin as**
375 **a treatment for S. Typhi or S. Paratyphi chronic carriage**

	Phillips	Simon	Molan	Diwan	Kaye
Participant characteristics					
Total no of participants	12	15	15	16	24
With gallstones, n (%)	0	5 (33)	4 (27)	3 (12)	12 (50)
Without gallstones, n (%)	0	10 (66)	11 (73)	7 (87)	7 (25)
Unknown gallstone status, n (%)	12 (100)	0 (0)	0 (0)	6 (38)	5 (21)
Known to have had cholecystectomy, n (%)	0 (0)	1 (7)	0	7 (44)	1 (4)
Demographics					
Age, mean	57	44	65	53	59
Age, range	23-81	7-62	48-77	36-67	33-83
Female, n (%)	7 (58)	10 (66)	13 (87)	7 (44)	18 (75)
Microbiological characteristics					
<i>S. Typhi</i> , n (%)	12 (100)	15 (100)	12 (100)	15 (94)	24 (100)
MIC to intervention drug, range (ug/mL)	NA	<1 - 2	< 1	0.5-2.5	NA
Intervention characteristics					
Intervention name	Ampicillin	Ampicillin	Amoxicillin	Ampicillin	Ampicillin
Administration method	PO	PO	PO	PO	PO
Intended daily regimen	1g QDS	75- 100mg/kg	2g TDS	1.25g QDS	1.5g QDS
Intended duration (day)	90	28	28	10-40	42
Addition of probenecid	No	No	No	No	Yes
Dosing details of initial course given					
Total daily dose, mean (g)	4	4	5.2	5.1	5.5
Total course duration, mean (days)	90	28	28	25	36
Total dose taken during course, mean (g)	360	112	146	128	198
Outcomes – eradication					
Minimum follow-up (months)	18	7	12	12	12
Total no patients eradicated after initial course, n (%)	9 (75)	13 (87)	11 (73)	7 (44)	9 (38)

<i>Eradicated in those with gallstones, n (%)</i>	0 (0)	4 (80)	3 (75)	0 (0)	4 (33)
<i>Eradicated in those without gallstones, n (%)</i>	0 (0)	8 (89)	9 (82)	4 (57)	5 (71)
<i>Eradicated in those with unknown gallstone status, n (%)</i>	9 (75)	0 (0)	0 (0)	3 (50)	0 (0)
<i>Eradicated in those with known cholecystectomy, n (%)</i>	0 (0)	1 (100)	0 (0)	3 (43)	0 (0)
<i>Total no of patients eradicated at end of follow-up, n (%)</i>	9 (75)	13 (87)	11 (92)	9 (56)	12 (50)
<i>Total no of antibiotic courses given, n</i>	12	17	15	21	31
<i>No of antibiotic courses resulting in successful eradication (%)</i>	9 (75)	13 (76)	11 (73)	9 (43)	12 (39)
<i>Outcomes – side effects</i>					
<i>Total side effects, n (%)</i>	8 (67)	10 (67)	7 (47)	NA	5 (21)
<i>Diarrhoea, n (%)</i>	5 (42)	8 (53)	3 (20)		1 (4)
<i>Rash, n (%)</i>	5 (42)	6 (40)	2 (13)		5 (21)
<i>Anaphylaxis</i>	1 (9)				
<i>Other, n (%)</i>	0 (0)	2 (20)	3 (20)		

376

377

378

379 Overall, 101 patients were given a total of 115 courses of amox/amp (either PO
380 or IV). Most of these patients were female and 28% had confirmed gallstones.

381 Only one patient had *S. Paratyphi*. The dosing regimens were relatively high with
382 the mean daily dose of amoxicillin 4.5g/day but this varied significantly between
383 studies (range 3-5.5g/day). The mean duration of treatment was 37 days but
384 again this was highly variable between regimens (range 15-90 days).

385

386 The overall eradication proportion after a single course of amox/amp was 68%
387 but again, this was highly variable between studies (range 38-100%).

388

389 ***Effect of administration method on eradication***

390 There was only one study looking at the effect of IV ampicillin on chronic
391 carriage eradication proportion(28). The mean daily dose and total cumulative
392 dose of IV ampicillin used in this study were much lower than those used in the
393 oral studies (3g vs a mean of 4.7g for the oral studies). However, the eradication
394 proportion in this study was notably higher when compared to the oral
395 ampicillin studies (100% vs 60%, $p < 0.01$) with no failures described in the IV
396 arm.

397

398 ***Effect of dosing regimen and duration on eradication***

399 The total daily dose of amox/amp varied between 4 and 5.5g for the studies
400 using oral intervention, with the total drug given over the duration of the course
401 between 112g to 360g.

402

403 Overall comparisons between dosing regimen and duration are not possible as
404 different studies used widely variable dosing regimens and durations, often not
405 standardised within their own study population. Therefore, individual regimens
406 within studies were examined more closely to investigate for possible
407 associations of dosing or duration with outcome.

408

409 In the Nolan et al study (36) two different dosing regimens of amoxicillin were
410 given. For those that tolerated it ($n = 10$) a dosing regimen of 2g of oral
411 ampicillin was administered three times daily (total daily dose of 6g) which had
412 a 90% success after one course of 28 days. In those who did not tolerate the
413 higher dose ($n= 5$) a lower dosing regimen of 1g oral ampicillin three times a day

414 (total daily dose of 3 grams) was started. This regimen only had a 40%
415 eradication proportion after 28 days, but the numbers were very small.

416

417 Similarly, in Phillips et al (23) those who completed the full dosing schedule had
418 a 90% eradication proportion whereas those who were unable to complete it
419 had a 0% eradication proportion, although these numbers are small and the
420 exact dosing regimens are not fully described in the paper.

421

422 In Dinbar et al (26) the initial course length was 10 days with a total of 52g of
423 ampicillin given over this time. This regimen had an eradication proportion of
424 38%. Over the period of the study the dose of ampicillin was increased to 200g
425 given over 40 days. The eradication proportion of this regimen was 57%. There
426 was no evidence to support a difference in eradication proportions between
427 dosing regimens ($p = 0.61$).

428

429 The Kaye study was the only study to use probenecid in addition to ampicillin.
430 Eradication proportions were lower in this study when compared to the other
431 studies where probenecid was not used (38% vs 76%).

432

433 Overall, we are unable to draw any firm conclusions from this data whether dose
434 or duration of this intervention effects eradication proportion although there is a
435 slight suggestion that higher daily dosing and intravenous dosing may be slightly
436 more effective.

437

438 ***Effect of gallstones on eradication***

439 All studies investigated for prior presence of gallstones except Phillips et al.
440 The eradication proportion was lower in those with gallstones compared to
441 those without gallstones (55% vs 79%, $p = 0.039$). Those with unknown
442 gallstone status had an eradication proportion of 62%, whereas those with a past
443 cholecystectomy only had an eradication proportion of 50%, although the
444 numbers in this group are small.

445

446 ***Effect of repeated courses on eradication***

447 After failing an initial course of therapy some patients were re-treated with a
448 second or third course. In Kaye et al six patients who failed an initial course were
449 re-treated with further courses of ampicillin. Of these only two were successfully
450 eradicated (27). In Dinbar et al four patients who initially failed therapy were
451 successfully treated with higher dosing regimens of ampicillin (26). In Simon et
452 al one patient was re-treated twice with prolonged six-week courses of
453 ampicillin which did not result in eradication (24). In total, of the 11 patients that
454 were re-treated, the eradication proportion was only 36%.

455

456 ***Side effects***

457 A third of patients in the ampicillin studies suffered side effects from their
458 therapy. Rash and diarrhoea were the most common side effects and in two
459 studies this resulted in a modification to therapy (31,34). In the IV amoxicillin
460 trial side effects were minimal. However, side effects were not routinely
461 reported across the studies.

462

463 **Comparing antimicrobial groups**

464 Fluoroquinolones have a higher overall eradication proportion than amox/amp
465 (92% vs 68%, $p = 0.02$). In those with gallstones the eradication proportion
466 remains higher in those taking a Fq compared to those taking amox/amp but this
467 is not significant (82% vs 55%, $p = 0.16$).

468

469

470 **Discussion**

471 This is the first systematic review on the efficacy of antimicrobial agents for
472 treatment of enteric fever chronic carriage. A total of 126 participants in 8
473 studies were included in this review and two intervention groups were
474 identified: Fq and amox/amp. Overall eradication proportion was higher in the
475 Fq compared to the amox/amp group (92% vs 68%, $p = 0.02$), but eradication
476 proportions varied highly across the included studies.

477

478 These findings are consistent with the limited existing guidelines available on
479 treatment of chronic carriage. As previously stated, the only available guidance
480 for treatment of chronic carriers is from the WHO 2003 guidelines which
481 suggests a quinolone, amoxicillin or co-trimoxazole (12,15). In this review we
482 have not identified any specific evidence for use of co-trimoxazole. During the
483 screening process we did identify literature investigating the use of co-
484 trimoxazole in addition to other antimicrobials such as chloramphenicol,
485 kanamycin and penicillin (37–43). None of these studies met the criteria for
486 inclusion in this study, again highlighting the poor quality of available evidence

487 on this subject. Most of these studies were case reports, small case series or did
488 not report on necessary outcome data.

489

490 The findings of this systematic review should be interpreted with caution.

491 Firstly, the overall quality of the included studies was poor, with only one RCT

492 included. The remainder of the studies were case series or pre- and post- studies

493 with no control group and no blinding, which allowed for significant bias.

494 Furthermore, in most studies it was unclear how patients had been identified for

495 participation. Interventions were non-consistent within and across studies and

496 the total number of included patients is small, limiting statistical analysis and

497 overall conclusions.

498

499 Secondly, almost all the patients included in this study had *S. Typhi* chronic

500 carriage and therefore limited conclusions can be made about the effectiveness

501 of these antimicrobials on *S. Paratyphi* chronic carriage. With the rollout of the

502 typhoid conjugate vaccine and the likely associated decrease in incidence of *S.*

503 *Typhi*, the incidence of *S. Paratyphi* may start to rise (44). Given there is

504 currently no licensed vaccine for *S. Paratyphi* the role of treatment of carriers of

505 this condition may become increasingly important in reducing enteric fever

506 transmission and disease. This review identifies current large gaps in the

507 evidence base for the treatment of this neglected condition.

508

509 Thirdly, and perhaps most importantly, the included trials were all carried out

510 prior to widespread antimicrobial resistance of enteric fever. There are no

511 studies that have been carried out to assess treatment options for enteric fever

512 chronic carriage in patients with multi-drug resistant (MDR), Fq-resistant, or
513 indeed extensively-drug-resistant enteric fever. This data is therefore inadequate
514 to inform decisions regarding antimicrobial treatment of chronic carriage in the
515 modern-day era of drug-resistant enteric fever.

516

517 Further research needs be done to understand and improve treatment options
518 for enteric fever chronic carriers today. The first barrier to investigating
519 treatment interventions on chronic carriers is the accurate identification of
520 chronic carriers from the population. In the trials included in this study, regular
521 stool cultures were used to identify carriers over many years. This is logistically
522 challenging and not suitable for large-scale screening today, particularly in low-
523 resource endemic areas. Furthermore, as stool shedding is intermittent, the
524 sensitivity is low (45). Molecular and serological strategies to identify carriers
525 have been explored but do not perform well, particularly in endemic settings
526 (46,47). New methods to identify carriers such as antigen-specific antibodies and
527 biomarkers show promise but need further exploration (48,49).

528

529 Once carriers can be accurately identified, further work is needed to investigate
530 the effect of different interventions on this population. There is limited data on
531 the antimicrobial susceptibility of chronic carriage isolates and whether they
532 harbour similar resistance profiles to acute enteric fever strains. A study from
533 2012 in Nepal looking at *S. Typhi* and *S. Paratyphi* isolates identified from
534 cholecystectomies found lower rates of antimicrobial resistance in these strains,
535 compared to acute enteric fever isolates in the same area (50). This suggests that
536 chronic carriage strains may originate from older, drug-susceptible strains for

537 which Fq and Amp may still be effective. Previous work looking at the genetic
538 diversity of *S. Typhi* has suggested this may be due to two different evolutionary
539 methods within the population structure of *S. Typhi* (51).

540

541 Even if chronic carriage isolates do show reduced susceptibility to ciprofloxacin,
542 the excellent bile penetration of this antimicrobial (reaching 2500-4500% of
543 plasma concentrations in the bile(52)), may be sufficient to overcome the
544 relatively low minimum inhibitory concentration (MIC) (e.g. with MIC \leq 1)
545 isolates, although there is no patient outcome data to support this.

546

547 Alternative antimicrobials that have not been identified in this review may also
548 be effective in treating chronic carriage. Azithromycin is currently used to treat
549 uncomplicated enteric fever worldwide with good efficacy (53) but no studies
550 have examined the efficacy of azithromycin on enteric fever chronic carriage.
551 Azithromycin has good bile penetration (52) and a single case report suggests it
552 may eradicate non-typhoidal *Salmonella* carriage (54). It therefore may be a
553 good intervention for enteric fever chronic carriage treatment and is currently
554 the preferred treatment for Fq resistant chronic carriage eradication in the UK;
555 post-treatment monitoring will be used to assess outcome.

556

557 It is well understood that the gallbladder is an important niche for the
558 persistence of *S. Typhi* and *S. Paratyphi* and the development of carriage (12,55).
559 Accordingly, cholecystectomy has been used as treatment for chronic carriage in
560 the past (26,56,57). In addition to carrying a significant anaesthetic and surgical
561 risk this intervention does not guarantee elimination of the carrier state, with

562 success rates reported between 70-90%. Studies in this review also identify
563 multiple patients identified as carriers who had already undergone a prior
564 cholecystectomy. Hence, it is likely that there are other foci of infection outside
565 the gallbladder that also play an important role in *S. Typhi* and *S. Paratyphi*
566 persistence and carriage, for example the biliary tree, liver or lymph nodes(58).

567

568 Recently, murine models have shown that biofilm formation, on gallbladder
569 epithelium and cholesterol-rich gallstones, may play an important role in the
570 development of carriage and protect against antimicrobial treatment (55,59–63).

571 Prior guidance similarly states that carriers with underlying gallstones are
572 unlikely to be eradicated with antimicrobials alone (12,15). In contrast, this
573 review shows relatively good eradication proportions in those with gallstones,
574 particularly when Fq treatment was used, albeit lower than those without
575 gallstones. Furthermore, many of the identified carriers in this review were not
576 found to have gallstones, despite thorough investigation. It is evident that further
577 work is required to better understand the pathophysiology of chronic carriage to
578 allow the development of targeted interventions.

579

580 This review was limited by the high risk of bias in all included studies. Many
581 studies showed selection bias with undefined selection of participants and
582 exclusion of certain groups. The participants may not be a true representative of
583 the carrier population. Minimal data was reported from all studies with very
584 little statistical analysis performed. Particularly, the presence of gallstones was
585 not investigated or reported in all studies meaning conclusions on whether
586 gallstones affect the effect of antimicrobial eradication are uncertain.

587

588 Side effects of medications were also poorly reported across studies. Some
589 adverse events were linked to the intervention without obvious causality e.g.
590 ciprofloxacin causing haemoglobin drop, when this is not a known common side
591 effect. Furthermore, associations of Fq therapy that were not recognised when
592 these studies took place, for example tendinopathy and aneurysm rupture, may
593 have been under-reported. The recent realisation of potential significant side
594 effects of Fq use has also led to restrictions in their use and they may no longer
595 be suitable to treat patients with chronic carriage, again highlighting the need for
596 alternative treatment strategies (64,65).

597

598 In this review we excluded case reports or case series of less than 10 patients in
599 attempt to reduce bias but in doing so may have excluded studies with additional
600 interventions. Furthermore, the evidence relating to this topic is almost all more
601 than 30 years old and some full-text articles were not able to be accessed, some
602 of which may have otherwise been included in the final review. The strengths of
603 our study include a comprehensive search strategy, the use of two independent
604 reviewers throughout the process and the use of well-defined data extraction
605 and quality assessment tools.

606

607 In conclusion, this review identifies evidence for fluoroquinolones and
608 amoxicillin/ampicillin as antimicrobial interventions for treatment of enteric
609 fever chronic carriage. Fluoroquinolones are the most effective antimicrobial
610 intervention and should be recommended for first-line treatment of chronic
611 carriage where the isolate is susceptible, given the lack of evidence for any other

612 interventions. There is insufficient evidence to recommend empiric use of
613 fluoroquinolones or amoxicillin/ampicillin for enteric fever chronic carriage
614 today, due to significant changes in antimicrobial resistance over the last 30
615 years. Updated evidence on this neglected topic is required and should be a vital
616 component of global eradication strategies for enteric fever going forward.

617

618

619 **References**

620

- 621 1. Stanaway JD, Reiner RC, Blacker BF, Goldberg EM, Khalil IA, Troeger CE, et
622 al. The global burden of typhoid and paratyphoid fevers: a systematic
623 analysis for the Global Burden of Disease Study 2017. *Lancet Infect Dis*
624 [Internet]. 2019 Apr 1 [cited 2021 Mar 17];19(4):369–81. Available from:
625 <http://dx.doi.org/10.1016/>
- 626 2. T.M. V. Temporary and chronic carriers of *Salmonella typhi* and *Salmonella*
627 *paratyphi B*. *J Hyg (Lond)* [Internet]. 1948;(3):252–61. Available from:
628 <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emcl1&N>
629 [EWS=N&AN=280592805](http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emcl1&N)
- 630 3. Gonzalez-Escobedo G, Marshall JM, Gunn JS. Chronic and acute infection of
631 the gall bladder by *Salmonella Typhi*: Understanding the carrier state. *Nat*
632 *Rev Microbiol*. 2011;
- 633 4. Levine MM, Black RE, Lanata C. Precise estimation of the numbers of
634 chronic carriers of *salmonella typhi* in Santiago, Chile, an endemic area. *J*
635 *Infect Dis*. 1982;
- 636 5. Vogelsang TM, Bøe J. Temporary and chronic carriers of *Salmonella typhi*
637 and *Salmonella paratyphi B*. *J Hyg (Lond)*. 1948;
- 638 6. Ames WR, Saphir W, Baer WH, Plotke F. Treatment of typhoid carriers. *J*
639 *Am Med Assoc*. 1942;119:582.
- 640 7. Mortimer PP. Mr N the milker, and Dr Koch's concept of the healthy
641 carrier. Vol. 353, *Lancet*. Elsevier; 1999. p. 1354–6.
- 642 8. Caygill CPJ, Hill MJ, Braddick M, Sharp JCM. Cancer mortality in chronic
643 typhoid and paratyphoid carriers. *Lancet*. 1994;
- 644 9. Nath G, Singh H, Shukla VK. Chronic typhoid carriage and carcinoma of the
645 gallbladder. *European Journal of Cancer Prevention*. 1997.
- 646 10. Dutta U, Garg PK, Kumar R, Tandon RK. Typhoid carriers among patients
647 with gallstones are at increased risk for carcinoma of the gallbladder. *Am J*
648 *Gastroenterol*. 2000;
- 649 11. Nagaraja V, Eslick GD. Systematic review with meta-analysis: The
650 relationship between chronic *Salmonella typhi* carrier status and gall-
651 bladder cancer. *Alimentary Pharmacology and Therapeutics*. 2014.
- 652 12. Gunn JS, Marshall JM, Baker S, Dongol S, Charles RC, Ryan ET. *Salmonella*

- 653 chronic carriage: Epidemiology, diagnosis, and gallbladder persistence
654 [Internet]. Vol. 22, Trends in Microbiology. Elsevier Ltd; 2014 [cited 2021
655 Mar 17]. p. 648–55. Available from: [/pmc/articles/PMC4252485/](#)
656 13. Gal-Mor O. Persistent infection and long-term carriage of typhoidal and
657 nontyphoidal salmonellae. *Clinical Microbiology Reviews*. 2019.
658 14. Parry CM, Hein TT, Dougan G, White NJ, Farrar JJ. Typhoid fever. *New*
659 *England Journal of Medicine*. 2002.
660 15. World Health Organization WHO Background document: The diagnosis,
661 treatment and prevention of typhoid fever Communicable Disease
662 Surveillance and Response Vaccines and Biologicals [Internet]. 2003 [cited
663 2021 Feb 23]. Available from: www.who.int/vaccines-documents/
664 16. Browne AJ, Kashef Hamadani BH, Kumaran EAP, Rao P, Longbottom J,
665 Harriss E, et al. Drug-resistant enteric fever worldwide, 1990 to 2018: A
666 systematic review and meta-analysis. *BMC Med* [Internet]. 2020 Jan 3
667 [cited 2021 Mar 17];18(1):1–22. Available from:
668 <https://doi.org/10.1186/s12916-019-1443-1>
669 17. C. B. Screening, phylogenetic analysis and antibiotic sensitivity pattern of
670 *Salmonella enterica* serovar Typhi isolates from typhoid asymptomatic
671 carriers. *Asian Pac J Trop Med* [Internet]. 2011;4(10):769–72. Available
672 from:
673 [http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed12&](http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed12&NEWS=N&AN=362795595)
674 [NEWS=N&AN=362795595](http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed12&NEWS=N&AN=362795595)
675 18. Qamar FN, Yousafzai MT, Sultana S, Baig A, Shakoor S, Hirani F, et al. A
676 Retrospective Study of Laboratory-Based Enteric Fever Surveillance,
677 Pakistan, 2012–2014. *J Infect Dis* [Internet]. 2018 Nov 10 [cited 2021 Mar
678 17];218(suppl_4):S201–5. Available from:
679 https://academic.oup.com/jid/article/218/suppl_4/S201/5060309
680 19. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et
681 al. The PRISMA 2020 statement: An updated guideline for reporting
682 systematic reviews. *The BMJ*. 2021.
683 20. Study Quality Assessment Tools | NHLBI, NIH [Internet]. [cited 2021 Mar
684 29]. Available from: [https://www.nlm.nih.gov/health-topics/study-](https://www.nlm.nih.gov/health-topics/study-quality-assessment-tools)
685 [quality-assessment-tools](https://www.nlm.nih.gov/health-topics/study-quality-assessment-tools)
686 21. C. F, J.G. MJ, C. V, I. P, V. S, G.L. D, et al. Efficacy of ciprofloxacin in the
687 treatment of chronic typhoid carriers. *J Infect Dis* [Internet].
688 1988;157(6):1235–9. Available from:
689 [http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed4&N](http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed4&NEWS=N&AN=18164989)
690 [EWS=N&AN=18164989](http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed4&NEWS=N&AN=18164989)
691 22. E. G, J.G. G, L. B, J.C. P, C. C, J. L, et al. Use of norfloxacin to treat chronic
692 typhoid carriers. *J Infect Dis* [Internet]. 1988;157(6):1221–5. Available
693 from:
694 [http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed4&N](http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed4&NEWS=N&AN=18164987)
695 [EWS=N&AN=18164987](http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed4&NEWS=N&AN=18164987)
696 23. Treatment of chronic typhoid carriers with ampicillin. *JAMA* [Internet].
697 1971;217(7):913–5. Available from:
698 [http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed1&N](http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed1&NEWS=N&AN=91440054)
699 [EWS=N&AN=91440054](http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed1&NEWS=N&AN=91440054)
700 24. Simon HJ, Miller RC. Ampicillin in the Treatment of Chronic Typhoid
701 Carriers. *N Engl J Med*. 1966;

- 702 25. NOLAN CM, ROSENFELD J. ANTIBIOTIC SUSCEPTIBILITY OF
703 SALMONELLA-TYPHI FROM CHRONIC ENTERIC CARRIERS. *Curr Ther Res*
704 *Exp.* 1977;21(5):736–40.
- 705 26. Dinbar A, Altmann G, Tulcinsky DB. The treatment of chronic biliary
706 Salmonella carriers. *Am J Med.* 1969;
- 707 27. Kaye D, Merselis JGJ, Connolly S, Hook EW. Treatment of chronic enteric
708 carriers of Salmonella typhosa with ampicillin. *Ann N Y Acad Sci* [Internet].
709 1967;145(2):429–35. Available from:
710 <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med1&NEWS=N&AN=5284273>
711
- 712 28. Scioli C, Fiorentino F, Sasso G. Treatment of Salmonella typhi carriers with
713 intravenous ampicillin. *J Infect Dis* [Internet]. 1972;125(2):170–3.
714 Available from:
715 <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med1&NEWS=N&AN=5007553>
716
- 717 29. Gotuzzo E, Guerra JG, Benavente L, Palomino JC, Carrillo C, Lopera J, et al.
718 Use of norfloxacin to treat chronic typhoid carriers. *J Infect Dis* [Internet].
719 1988;157(6):1221–5. Available from:
720 <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed4&NEWS=N&AN=18164987>
721
- 722 30. C. F, J.G. MJ, C. V, I. P, V. S, G.L. D, et al. Efficacy of ciprofloxacin in the
723 treatment of chronic typhoid carriers. *J Infect Dis* [Internet].
724 1988;157(6):1235–9. Available from:
725 <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed4&NEWS=N&AN=18164989>
726
- 727 31. C.M. N, Nolan CM, White PC. Treatment of typhoid carriers with
728 amoxicillin. Correlates of successful therapy. *J Am Med Assoc* [Internet].
729 1978;239(22):2352–4. Available from:
730 <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed2&NEWS=N&AN=8388271>
731
- 732 32. Simon HJ, Miller RC. Ampicillin in the treatment of chronic typhoid
733 carriers. Report on fifteen treated cases and a review of the literature. *N*
734 *Engl J Med* [Internet]. 1966;274(15):807–15. Available from:
735 <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med1&NEWS=N&AN=5908876>
736
- 737 33. Ames WR, Robins M. Age and Sex as Factors in the Development of the
738 Typhoid Carrier State, and a Method for Estimating Carrier Prevalence. *Am*
739 *J Public Heal Nations Heal.* 1943;
- 740 34. Treatment of chronic typhoid carriers with ampicillin. *JAMA* (Chicago, Ill)
741 [Internet]. 1971;217(7):913–5. Available from:
742 <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emcl1&NEWS=N&AN=292051214>
743
- 744 35. C. F, J.G. MJ, C. V, I. P, V. S, G.L. D. Efficacy of ciprofloxacin in the treatment
745 of chronic typhoid carriers. *J Infect Dis* [Internet]. 1988;157(6):1235–9.
746 Available from:
747 <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed4&NEWS=N&AN=18164989>
748
- 749 36. Nolan CM, White PC. Treatment of Typhoid Carriers With Amoxicillin:
750 Correlates of Successful Therapy. *JAMA J Am Med Assoc.* 1978;

- 751 37. H. P, H. K, K.H. S, G. V. Treatment of chronic carriers of Salmonella typhi
752 and Salmonella paratyphi B with trimethoprim sulfamethoxazole. J Infect
753 Dis. 1973;
- 754 38. Tauchnitz C, Horn M, Forster E. [Treatment of S. typhi and S. paratyphi B
755 carriers]. Zur Sanierung von Typhus- und Paratyphus-B-
756 Dauerausscheidern [Internet]. 1972;27(15):647-54. Available from:
757 [http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med1&NE](http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med1&NEWS=N&AN=4485581)
758 [WS=N&AN=4485581](http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med1&NEWS=N&AN=4485581)
- 759 39. Brodie J, Macqueen IA, Livingstone D. Effect of Trimethoprim-
760 Sulphamethoxazole on Typhoid and Salmonella Carriers. Br Med J. 1970;
- 761 40. CROCKER TT, GELPERIN A, Th.T. C. Treatment of the typhoid carrier state
762 with chloramphenicol. Yale J Biol Med [Internet]. 1950;23(2):119-24.
763 Available from:
764 [http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emcl1&N](http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emcl1&NEWS=N&AN=280603709)
765 [EWS=N&AN=280603709](http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emcl1&NEWS=N&AN=280603709)
- 766 41. C.A. R, RUMBULL CA, MOORE LG, C.A. R, RUMBALL CA, MOORE LG, et al.
767 Treatment of a chronic typhoid carrier with chloromycetin. Br Med J
768 [Internet]. 1949;1(4612):943. Available from:
769 [http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed1&N](http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed1&NEWS=N&AN=608414974)
770 [EWS=N&AN=608414974](http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed1&NEWS=N&AN=608414974)
- 771 42. T.E. W, J.E. S, WOODWARD TE, SMADEL JE, LEY HLJ, T.E. W, et al.
772 Chloramphenicol and other antibiotics in the treatment of typhoid fever
773 and typhoid carriers. J Clin Invest [Internet]. 1950;29(1):87-99. Available
774 from:
775 [http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med1&NE](http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med1&NEWS=N&AN=15399518)
776 [WS=N&AN=15399518](http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med1&NEWS=N&AN=15399518)
- 777 43. A.M. G, R.N. P. Treatment and follow-up studies with co-trimoxazole in
778 enteric fever and in typhoid carriers. J Antimicrob Chemother [Internet].
779 1975;1(1):51-4. Available from:
780 [http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed2&N](http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed2&NEWS=N&AN=5551869)
781 [EWS=N&AN=5551869](http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed2&NEWS=N&AN=5551869)
- 782 44. Dong B-Q, Yang J, Wang X-Y, Gong J, von Seidlein L, Wang M-L, et al. Trends
783 and disease burden of enteric fever in Guangxi province, China, 1994-
784 2004. Bull World Health Organ. 2010;
- 785 45. BOKKENHEUSER V. DETECTION OF TYPHOID CARRIERS. American
786 journal of public health and the nation's health. 1964.
- 787 46. Nath G, Maurya P, Gulati AK, Singh TB, Srivastava R, Kumar K, et al.
788 Comparison of Vi serology and nested PCR in diagnosis of chronic typhoid
789 carriers in two different study populations in typhoid endemic area of
790 India. Southeast Asian J Trop Med Public Health. 2010;
- 791 47. Gupta A, My Thanh NT, Olsen SJ, Sivapalasingam S, My Trinh TT, Phuong
792 Lan NT, et al. Evaluation of community-based serologic screening for
793 identification of chronic Salmonella Typhi carriers in Vietnam. Int J Infect
794 Dis. 2006 Jul 1;10(4):309-14.
- 795 48. Charles RC, Sultana T, Alam MM, Yu Y, Wu-Freeman Y, Bufano MK, et al.
796 Identification of Immunogenic Salmonella enterica Serotype Typhi
797 Antigens Expressed in Chronic Biliary Carriers of S. Typhi in Kathmandu,
798 Nepal. PLoS Negl Trop Dis [Internet]. 2013 [cited 2021 Mar 29];7(8).
799 Available from: <https://pubmed.ncbi.nlm.nih.gov/23936575/>

- 800 49. Franklin F, Chong CW, Chua LH, Anthony AA, Liew MWO, Aziah I, et al.
801 Evaluation of Salmonella Typhi antigen YncE alongside HlyE for the
802 detection of typhoid fever and its carriers. *Med Microbiol Immunol*. 2020;
803 50. D. C, J. M, D. K, C.M. H, J.L. S, J.A. K, et al. Drug resistance in Salmonella
804 enterica serotype Typhi isolated from chronic typhoid carriers. *Clin Infect*
805 *Dis [Internet]*. 2015;12(1):536–8. Available from:
806 <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed1&N>
807 [EWS=N&AN=4495214](http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed1&N)
808 51. P. R, F.-X. W, C. D, S. BBB, S. BBB, T.C. N, et al. Evolutionary history of
809 Salmonella Typhi. *Science (80-) [Internet]*. 2006;314(5803):1301–4.
810 Available from: <http://www.sciencemag.org>
811 52. Gilbert Davi, Chambers Henry, Saag Michael PA. Sanford Guide to
812 Antimicrobial Therapy 2020. Sanford Guide to Antimicrobial Therapy
813 2020. 2020.
814 53. Effa EE, Bukirwa H. Azithromycin for treating uncomplicated typhoid and
815 paratyphoid fever (enteric fever) [Internet]. *Cochrane Database of*
816 *Systematic Reviews*. John Wiley and Sons Ltd; 2008 [cited 2021 Mar 29].
817 Available from: <https://pubmed.ncbi.nlm.nih.gov/18843701/>
818 54. Imbert P, Rapp C, Lecoules S, Garrabe E, Debord T. Eradication of
819 multiresistant Salmonella Hadar convalescent-phase carriage with
820 azithromycin. *Clin Microbiol Infect*. 2003 Nov;9(11):1155–6.
821 55. Gonzalez-Escobedo G, Marshall JM, Gunn JS, G. G-E, J.M. M, Gonzalez-
822 Escobedo G, et al. Chronic and acute infection of the gall bladder by
823 Salmonella Typhi: Understanding the carrier state. *Nat Rev Microbiol*
824 [Internet]. 2011;9(1):9–14. Available from:
825 <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed12&>
826 [NEWS=N&AN=51172587](http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed12&)
827 56. Vogelsang TM. The campaign against typhoid and paratyphoid B in
828 western Norway. Results of cholecystectomy. *J Hyg (Lond)*. 1964;
829 57. Main RG. Treatment of the chronic alimentary enteric carrier. *Br Med J*.
830 1961;
831 58. Nath G, Pratap CB, Patel SK, Gulati AK, Tripathi SK. Isolation of Salmonella
832 typhi from apparently healthy liver. *Infect Genet Evol*. 2011;
833 59. J. M, D. K, C.M. H, J.L. S, J.A. K, J.R. F, et al. Identification of a Small Molecule
834 Anti-biofilm Agent Against Salmonella enterica. *Front Microbiol [Internet]*.
835 2018;9(NOV):2804. Available from:
836 <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=premed1&N>
837 [WS=N&AN=30515144](http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=premed1&N)
838 60. Prouty AM, Schwesinger WH, Gunn JS, A.M. P, W.H. S, Prouty AM, et al.
839 Biofilm formation and interaction with the surfaces of gallstones by
840 Salmonella spp. *Infect Immun [Internet]*. 2002;70(5):2640–9. Available
841 from:
842 <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed7&N>
843 [EWS=N&AN=34408410](http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed7&N)
844 61. Crawford RW, Rosales-Reyes R, Ramírez-Aguilar MDLL, Chapa-Azuela O,
845 Alpuche-Aranda C, Gunn JS. Gallstones play a significant role in Salmonella
846 spp. gallbladder colonization and carriage. *Proc Natl Acad Sci U S A*. 2010;
847 62. J.F. G, H. A, J. L, L. D, Gonzalez JF, Alberts H, et al. Biofilm Formation
848 Protects Salmonella from the Antibiotic Ciprofloxacin In Vitro and In Vivo

- 849 in the Mouse Model of chronic Carriage. *Sci Rep* [Internet]. 2018;8(1):222.
850 Available from:
851 <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med15&N>
852 [EWS=N&AN=29317704](http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med15&N)
853 63. Adcox HE, Vasicek EM, Dwivedi V, Hoang K V, Turner J, Gunn JS, et al.
854 *Salmonella* extracellular matrix components influence biofilm formation
855 and gallbladder colonization. *Infect Immun* [Internet]. 2016;84(11):3243–
856 51. Available from:
857 <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med13&N>
858 [EWS=N&AN=27600501](http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med13&N)
859 64. Persson R, Jick S. Clinical implications of the association between
860 fluoroquinolones and tendon rupture: The magnitude of the effect with
861 and without corticosteroids. *Br J Clin Pharmacol*. 2019;
862 65. Raine J. Fluoroquinolone antibiotics: New restrictions and precautions due
863 to very rare reports of disabling and potentially long-lasting or irreversible
864 side effects. Medicines & Healthcare products Regulatory Agency. 2019.
865
866

867 **Supporting Information**

868


869 **S1. PRISMA Checklist**

870 **S2. Search strategy**

871 **S3. Protocol**

872 **S4. R script for comparison of categorical variables**

873



From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit www.prisma-statement.org.